Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

PURPOSE: To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma. PATIENTS AND METHODS: Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and...

詳細記述

保存先:
書誌詳細
主要な著者: Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2009
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668968/
https://ncbi.nlm.nih.gov/pubmed/19255334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.1561
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料